Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial

Review of ACCORD study (n=7,275) found, as compared to standard intervention, intensive glucose treatment and intensive blood pressure intervention reduced cardiovascular autonomic neuropathy (CAN) by 16% and 25% respectively. Fenofibrate did not have an effect on CAN.

Source:

Diabetes Care